Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

INCY Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 17.50%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $9,447,366.86

Incyte Insider Trading History Chart

Incyte Share Price & Price History

^$54.70

▼ -0.48 (-0.87%)

As of 12/8/2023 01:00 AM ET

Days: 30 | 90 | 365

All the trading advice you’ve ever received boils down to this

From DTI Trader | Ad

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

Drop everything and learn about the Income Calendar now.

Incyte Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/30/2023	Maria E. Pasquale	EVP	Sell	60,024	$84.74	$5,086,433.76	68,524
1/26/2023	Vijay K. Iyengar	EVP	Sell	7,000	$85.00	$595,000.00	42,835
1/4/2023	Steven H. Stein	EVP	Sell	28,399	$79.78	$2,265,672.22	109,021
12/23/2022	Vijay K. Iyengar	EVP	Sell	17,324	$80.80	$1,399,779.20	37,855
12/19/2022	Thomas Tray	Insider	Sell	1,223	$82.16	$100,481.68	16,606
7/22/2022	Thomas Tray	Insider	Sell	1,564	$83.13	$130,015.32	17,702
7/7/2022	Vijay K. Iyengar	EVP	Sell	5,787	$79.38	$459,372.06	40,313
4/8/2022	Barry P Flannelly	EVP	Sell	43,993	$83.49	$3,672,975.57	65,163
3/10/2022	Bros. Advisors Lp Baker	Director	Buy	218,563	$73.13	$15,983,512.19
3/8/2022	Bros. Advisors Lp Baker	Director	Buy	100,000	$70.67	$7,067,000.00
2/22/2022	Bros. Advisors Lp Baker	Director	Buy	99,800	$68.07	$6,793,386.00
2/17/2022	Bros. Advisors Lp Baker	Director	Buy	292,972	$67.74	$19,845,923.28
1/31/2022	Jonathan Elliott Dickinson	EVP	Sell	7,375	$74.19	$547,151.25
1/7/2022	Paula J. Swain	EVP	Sell	10,870	$73.31	$796,879.70
12/23/2021	Wendy L. Dixon	Director	Sell	20,000	$22.05	$441,000.00
12/17/2021	Bros. Advisors Lp Baker	Director	Buy	1,075,872	$72.80	$78,323,481.60
12/15/2021	Bros. Advisors Lp Baker	Director	Buy	350,332	$71.51	$25,052,241.32
10/1/2021	Dashyant Dhanak	EVP	Sell	389	$68.67	$26,712.63
9/1/2021	Dashyant Dhanak	EVP	Sell	388	$76.71	$29,763.48
7/29/2021	Vijay K. Iyengar	EVP	Sell	4,911	$78.29	$384,482.19
6/29/2021	Wenquing Yao	EVP	Sell	27,194	$85.37	$2,321,551.78
4/1/2021	Dashyant Dhanak	EVP	Sell	396	$81.57	$32,301.72
3/29/2021	Michael James Morrissey	EVP	Sell	20,000	$81.08	$1,621,600.00
2/23/2021	Herve Hoppenot	President	Buy	12,925	$77.37	$1,000,007.25
1/25/2021	Wenquing Yao	EVP	Sell	21,545	$100.00	$2,154,500.00	145,343

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

From Autonomix | Ad

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

Invest in Autonomix today.

SEC Filings (Institutional Ownership Changes) for Incyte (NASDAQ:INCY)

92.61% of Incyte stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Incyte Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
12/7/2023	Hudson Bay Capital Management LP	511,785	$29.57M	0.2%	-23.6%	0.228%
12/1/2023	Wellington Management Group LLP	88,489	$5.11M	0.0%	+14.5%	0.039%
11/30/2023	American Century Companies Inc.	248,771	$14.37M	0.0%	+25.7%	0.111%
11/30/2023	Neo Ivy Capital Management	17,908	$1.04M	0.5%	N/A	0.008%
11/24/2023	Deutsche Bank AG	580,298	$33.52M	0.0%	-41.4%	0.259%
11/24/2023	EP Wealth Advisors LLC	3,532	$0.20M	0.0%	-96.1%	0.002%
11/22/2023	Polar Capital Holdings Plc	590,000	$34.08M	0.2%	-45.9%	0.263%
11/22/2023	Public Sector Pension Investment Board	19,790	$1.14M	0.0%	+12.3%	0.009%
11/21/2023	Walleye Capital LLC	41,229	$2.38M	0.0%	+20.3%	0.018%
11/21/2023	Comerica Bank	57,724	$3.34M	0.0%	+31.4%	0.026%
11/17/2023	Diversified Trust Co	13,084	$0.76M	0.0%	+61.1%	0.006%
11/17/2023	Jacobs Levy Equity Management Inc.	2,085,465	$120.48M	0.7%	+17.7%	0.931%
11/16/2023	Creative Planning	10,478	$0.61M	0.0%	+8.0%	0.005%
11/16/2023	Ashford Capital Management Inc.	448,844	$25.93M	3.8%	-2.2%	0.200%
11/16/2023	Tudor Investment Corp Et Al	117,564	$6.79M	0.1%	+2.6%	0.052%
11/16/2023	Public Employees Retirement System of Ohio	77,860	$4.50M	0.0%	-7.4%	0.035%
11/16/2023	Morgan Stanley	2,119,738	$122.46M	0.0%	+9.7%	0.946%
11/15/2023	Toroso Investments LLC	14,977	$0.87M	0.0%	+2.6%	0.007%
11/15/2023	iA Global Asset Management Inc.	3,971	$0.23M	0.0%	-49.9%	0.002%
11/15/2023	The Manufacturers Life Insurance Company	191,465	$11.06M	0.0%	-73.1%	0.085%
11/15/2023	GSA Capital Partners LLP	39,170	$2.26M	0.2%	+517.0%	0.017%
11/15/2023	Royal Bank of Canada	987,052	$57.02M	0.0%	+85.3%	0.440%
11/15/2023	Royal London Asset Management Ltd.	64,877	$3.75M	0.0%	+2.9%	0.029%
11/15/2023	Sectoral Asset Management Inc.	9,645	$0.56M	0.1%	+17.9%	0.004%
11/15/2023	Sei Investments Co.	187,744	$10.85M	0.0%	+37.5%	0.084%
11/15/2023	JPMorgan Chase & Co.	434,521	$25.10M	0.0%	-1.9%	0.194%
11/15/2023	Legal & General Group Plc	1,736,924	$100.34M	0.0%	-3.0%	0.775%
11/15/2023	Lido Advisors LLC	87,146	$5.03M	0.0%	N/A	0.039%
11/15/2023	AIMZ Investment Advisors LLC	63,062	$3.64M	1.6%	-0.6%	0.028%
11/15/2023	Ameriprise Financial Inc.	931,966	$53.84M	0.0%	+33.0%	0.416%
11/15/2023	Armistice Capital LLC	1,036,000	$59.85M	0.9%	-41.7%	0.462%
11/15/2023	AXQ Capital LP	22,400	$1.29M	0.5%	N/A	0.010%
11/15/2023	Advisors Asset Management Inc.	23,688	$1.37M	0.0%	+2.9%	0.011%
11/15/2023	Alberta Investment Management Corp	196,976	$11.38M	0.1%	+130.5%	0.088%
11/15/2023	AQR Capital Management LLC	1,249,162	$72.16M	0.1%	+32.6%	0.557%
11/14/2023	Lazard Asset Management LLC	99,298	$5.74M	0.0%	+746.0%	0.044%
11/14/2023	Braidwell LP	294,900	$17.04M	0.5%	N/A	0.132%
11/14/2023	Caisse DE Depot ET Placement DU Quebec	308,839	$17.84M	0.1%	+283.3%	0.138%
11/14/2023	Schonfeld Strategic Advisors LLC	31,076	$1.80M	0.0%	-87.5%	0.014%
11/14/2023	Gotham Asset Management LLC	84,355	$4.87M	0.1%	+240.0%	0.038%
11/14/2023	Caxton Associates LP	47,817	$2.76M	0.4%	+29.5%	0.021%
11/14/2023	Sherbrooke Park Advisers LLC	32,223	$1.86M	0.6%	+166.3%	0.014%
11/14/2023	Teza Capital Management LLC	117,691	$6.80M	0.6%	+76.7%	0.053%
11/14/2023	California State Teachers Retirement System	287,615	$16.62M	0.0%	-2.7%	0.128%
11/14/2023	Toronto Dominion Bank	96,240	$5.56M	0.0%	-3.4%	0.043%
11/14/2023	Bank of Nova Scotia	24,541	$1.42M	0.0%	+14.8%	0.011%
11/14/2023	Tower Research Capital LLC TRC	11,634	$0.67M	0.0%	+44.9%	0.005%
11/14/2023	Qube Research & Technologies Ltd	1,087,611	$62.83M	0.2%	+68.7%	0.485%
11/14/2023	Treasurer of the State of North Carolina	89,217	$5.15M	0.0%	+0.4%	0.040%
11/14/2023	Trexquant Investment LP	161,645	$9.34M	0.2%	+2.9%	0.072%
11/14/2023	Vinva Investment Management Ltd	11,986	$0.70M	0.1%	+120.0%	0.005%
11/14/2023	MQS Management LLC	5,581	$0.32M	0.2%	+6.2%	0.002%
11/14/2023	Oak Associates Ltd. OH	25,685	$1.48M	0.1%	-7.1%	0.011%
11/14/2023	Profund Advisors LLC	25,720	$1.49M	0.1%	-5.1%	0.011%
11/13/2023	C M Bidwell & Associates Ltd.	1,695	$98K	0.1%	N/A	0.001%
11/13/2023	Connor Clark & Lunn Investment Management Ltd.	858,730	$49.61M	0.3%	+67.2%	0.383%
11/13/2023	Covestor Ltd	1,606	$93K	0.1%	+28.8%	0.001%
11/13/2023	Meiji Yasuda Asset Management Co Ltd.	29,113	$1.68M	0.1%	+163.2%	0.013%
11/13/2023	Northern Trust Corp	2,127,688	$122.92M	0.0%	+5.9%	0.949%
11/13/2023	Federated Hermes Inc.	864,710	$49.95M	0.1%	+145.2%	0.386%
11/13/2023	Stifel Financial Corp	21,129	$1.22M	0.0%	-17.6%	0.009%
11/13/2023	Mariner LLC	8,202	$0.47M	0.0%	+12.4%	0.004%
11/13/2023	Ontario Teachers Pension Plan Board	56,790	$3.28M	0.0%	+100.0%	0.025%
11/13/2023	LPL Financial LLC	45,023	$2.60M	0.0%	+16.4%	0.020%
11/13/2023	Dark Forest Capital Management LP	19,214	$1.11M	0.1%	N/A	0.009%
11/13/2023	Acadian Asset Management LLC	2,684,621	$155.05M	0.6%	+56.6%	1.198%
11/13/2023	Hsbc Holdings PLC	1,117,195	$64.55M	0.1%	+0.2%	0.499%
11/13/2023	UniSuper Management Pty Ltd	2,802	$0.16M	0.0%	-8.2%	0.001%
11/13/2023	V Square Quantitative Management LLC	3,397	$0.20M	0.1%	+1,083.6%	0.002%
11/13/2023	PAX Financial Group LLC	15,053	$0.87M	0.2%	+3.1%	0.007%
11/13/2023	CI Investments Inc.	3,634	$0.21M	0.0%	-12.4%	0.002%
11/13/2023	Aigen Investment Management LP	10,694	$0.62M	0.1%	-85.3%	0.005%
11/13/2023	Pearl River Capital LLC	56,980	$3.29M	0.5%	N/A	0.025%
11/13/2023	BNP PARIBAS ASSET MANAGEMENT Holding S.A.	25,218	$1.46M	0.0%	+24.9%	0.011%
11/13/2023	Mirabella Financial Services LLP	3,649	$0.21M	0.0%	N/A	0.002%
11/13/2023	Invesco Ltd.	3,922,045	$226.58M	0.1%	+3.2%	1.750%
11/13/2023	WINTON GROUP Ltd	5,518	$0.32M	0.0%	N/A	0.002%
11/13/2023	FMR LLC	1,556,751	$89.93M	0.0%	+38.2%	0.695%
11/13/2023	Envestnet Asset Management Inc.	39,541	$2.28M	0.0%	+113.0%	0.018%
11/13/2023	Nordea Investment Management AB	85,495	$4.97M	0.0%	+640.2%	0.038%
11/13/2023	Grantham Mayo Van Otterloo & Co. LLC	506,312	$29.25M	0.1%	+20.4%	0.226%
11/13/2023	Korea Investment CORP	94,270	$5.45M	0.0%	+31.0%	0.042%
11/13/2023	Rafferty Asset Management LLC	158,539	$9.16M	0.1%	+2.9%	0.071%
11/13/2023	Prudential PLC	37,267	$2.15M	0.0%	-6.4%	0.017%
11/13/2023	Aviva PLC	129,955	$7.51M	0.0%	-19.6%	0.058%
11/13/2023	DekaBank Deutsche Girozentrale	130,713	$7.65M	0.0%	+3.9%	0.058%
11/13/2023	PNC Financial Services Group Inc.	23,287	$1.35M	0.0%	+4.9%	0.010%
11/13/2023	E Fund Management Co. Ltd.	8,826	$0.51M	0.0%	-3.7%	0.004%
11/9/2023	Rhumbline Advisers	581,972	$33.62M	0.0%	+5.0%	0.260%
11/9/2023	Deutsche Bank AG	580,298	$33.52M	0.0%	-41.4%	0.259%
11/9/2023	Prudent Man Advisors LLC	6,641	$0.38M	0.2%	-2.8%	0.003%
11/9/2023	Citigroup Inc.	513,786	$29.68M	0.0%	+50.9%	0.229%
11/9/2023	Skandinaviska Enskilda Banken AB publ	272,939	$15.77M	0.1%	-37.7%	0.122%
11/9/2023	Andra AP fonden	139,500	$8.06M	0.5%	-7.1%	0.062%
11/9/2023	Blair William & Co. IL	56,410	$3.26M	0.0%	-31.2%	0.025%
11/9/2023	Commonwealth of Pennsylvania Public School Empls Retrmt SYS	37,397	$2.16M	0.0%	+15.8%	0.017%
11/9/2023	Texas Permanent School Fund Corp	38,433	$2.22M	0.0%	-1.0%	0.017%
11/9/2023	Mutual of America Capital Management LLC	26,084	$1.51M	0.0%	-2.3%	0.012%
11/9/2023	UBS Group AG	393,212	$22.72M	0.0%	-19.3%	0.175%
11/9/2023	Jupiter Asset Management Ltd.	812,919	$46.96M	0.5%	+16.4%	0.363%

Data available starting January 2016

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Today's Range

Now: $54.70

$54.30

$55.17

50 Day Range

MA: $54.98

$52.16

$58.81

52 Week Range

Now: $54.70

$50.27

$86.29

Volume

1,517,309 shs

Average Volume

1,633,933 shs

Market Capitalization

$12.26 billion

P/E Ratio

28.94

Dividend Yield

N/A

Beta

0.7

Who are the company insiders with the largest holdings of Incyte?: Incyte's top insider shareholders include:
Steven H Stein (EVP)
Maria E Pasquale (EVP)
Barry P Flannelly (EVP)
Vijay K Iyengar (EVP)
Thomas Tray (Insider)
Bros Advisors Lp Baker (Director)
Jonathan Elliott Dickinson (EVP)
Paula J Swain (EVP)
Wendy L Dixon (Director)
Learn More about top insider investors at Incyte.
Who are the major institutional investors of Incyte?: Incyte's top institutional investors include:
Invesco Ltd. — 1.75%
Acadian Asset Management LLC — 1.20%
Northern Trust Corp — 0.95%
Morgan Stanley — 0.95%
Jacobs Levy Equity Management Inc. — 0.93%
Legal & General Group Plc — 0.78%
Learn More about top institutional investors of Incyte stock.
Which institutional investors are selling Incyte stock?: During the previous quarter, INCY stock was sold by these institutional investors:
Armistice Capital LLC
The Manufacturers Life Insurance Company
Polar Capital Holdings Plc
Deutsche Bank AG
Deutsche Bank AG
Schonfeld Strategic Advisors LLC
Skandinaviska Enskilda Banken AB publ
Hudson Bay Capital Management LP
In the last year, company insiders that have sold Incyte company stock include:
Steven H Stein (EVP)
Maria E Pasquale (EVP)
Barry P Flannelly (EVP)
Vijay K Iyengar (EVP)
Learn More investors selling Incyte stock.
Which institutional investors are buying Incyte stock?: Within the previous quarter, INCY stock was purchased by institutional investors including:
Los Angeles Capital Management LLC
Acadian Asset Management LLC
Federated Hermes Inc.
Royal Bank of Canada
Qube Research & Technologies Ltd
FMR LLC
Connor Clark & Lunn Investment Management Ltd.
Jacobs Levy Equity Management Inc.